within Pharmacolibrary.Drugs.ATC.L;

model L04AC17
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5.333333333333334e-06,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0108,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0038,
    k12             = 0.62,
    k21             = 0.62
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AC17</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. It is approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with moderate-to-severe plaque psoriasis. Data from population PK models include both sexes, typical adult age range.</p><h4>References</h4><ol><li><p>Khalilieh, S, et al., &amp; Montgomery, D (2018). Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 123(3) 294–300. DOI:<a href=&quot;https://doi.org/10.1111/bcpt.13001&quot;>10.1111/bcpt.13001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29510001/&quot;>https://pubmed.ncbi.nlm.nih.gov/29510001</a></p></li><li><p>Sinclair, R, &amp; Thirthar Palanivelu, V (2019). Tildrakizumab for the treatment of psoriasis. <i>Expert review of clinical immunology</i> 15(1) 5–12. DOI:<a href=&quot;https://doi.org/10.1080/1744666X.2019.1544493&quot;>10.1080/1744666X.2019.1544493</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30394141/&quot;>https://pubmed.ncbi.nlm.nih.gov/30394141</a></p></li><li><p>Khalilieh, S, et al., &amp; Iwamoto, M (2018). Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis. <i>British journal of clinical pharmacology</i> 84(10) 2292–2302. DOI:<a href=&quot;https://doi.org/10.1111/bcp.13670&quot;>10.1111/bcp.13670</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29926968/&quot;>https://pubmed.ncbi.nlm.nih.gov/29926968</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AC17;
